Samsung Biologics Reports Third Quarter 2026 Financial Results

Samsung Biologics reported third-quarter revenue of KRW 1,490 billion and operating profit of KRW 640 billion, supported by Plants 1 through 4 operating at full capacity and increasing contributions from Plant 5. The company raised its 2026 revenue growth guidance to 20% and is advancing strategic investments, including the planned acquisition of PolyPeptide Group and a KRW 3 trillion rights offering to fund these investments.